Unknown

Dataset Information

0

An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy.


ABSTRACT: Immunochemotherapy combines a chemotherapeutic agent with an immune-modulating agent and represents an attractive approach to improve cancer therapy. However, the success of immunochemotherapy is hampered by the lack of a strategy to effectively co-deliver the two therapeutics to the tumours. Here we report the development of a dual-functional, immunostimulatory nanomicellar carrier that is based on a prodrug conjugate of PEG with NLG919, an indoleamine 2,3-dioxygenase (IDO) inhibitor currently used for reversing tumour immune suppression. An Fmoc group, an effective drug-interactive motif, is also introduced into the carrier to improve the drug loading capacity and formulation stability. We show that PEG2k-Fmoc-NLG alone is effective in enhancing T-cell immune responses and exhibits significant antitumour activity in vivo. More importantly, systemic delivery of paclitaxel (PTX) using the PEG2k-Fmoc-NLG nanocarrier leads to a significantly improved antitumour response in both breast cancer and melanoma mouse models.

SUBMITTER: Chen Y 

PROVIDER: S-EPMC5103075 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy.

Chen Yichao Y   Xia Rui R   Huang Yixian Y   Zhao Wenchen W   Li Jiang J   Zhang Xiaolan X   Wang Pengcheng P   Venkataramanan Raman R   Fan Jie J   Xie Wen W   Ma Xiaochao X   Lu Binfeng B   Li Song S  

Nature communications 20161107


Immunochemotherapy combines a chemotherapeutic agent with an immune-modulating agent and represents an attractive approach to improve cancer therapy. However, the success of immunochemotherapy is hampered by the lack of a strategy to effectively co-deliver the two therapeutics to the tumours. Here we report the development of a dual-functional, immunostimulatory nanomicellar carrier that is based on a prodrug conjugate of PEG with NLG919, an indoleamine 2,3-dioxygenase (IDO) inhibitor currently  ...[more]

Similar Datasets

| S-EPMC6513707 | biostudies-literature
| S-EPMC10766965 | biostudies-literature
| S-EPMC10197197 | biostudies-literature
| S-EPMC4224520 | biostudies-literature
| S-EPMC10831265 | biostudies-literature
| S-EPMC8241031 | biostudies-literature
| S-EPMC6836385 | biostudies-literature
| S-EPMC10140750 | biostudies-literature
| S-EPMC4042837 | biostudies-literature
| S-EPMC2918704 | biostudies-literature